Citi Pharma (KAR:CPHL) Short-Term Debt: ₨0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨73.40
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Short-Term Debt?

Citi Pharma KAR:CPHL +0.86% 15 Short-Term Debt is ₨0.00 Mil as of . 20. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Citi Pharma's Short-Term Debt for the quarter that ended in . 20 was ₨0.00 Mil.

Citi Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Citi Pharma Short-Term Debt Related Terms

Citi Pharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Short-Term Debt Chart

Citi Pharma Annual Data
Trend
Short-Term Debt

Citi Pharma Semi-Annual Data
Short-Term Debt
KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₨0.00 Mil mean?
Citi Pharma (KAR:CPHL) has a Short-Term Debt of ₨0.00 Mil as of . 20.
Is Citi Pharma's Short-Term Debt too high?
Citi Pharma's current Short-Term Debt is ₨0.00 Mil. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's Short-Term Debt compare to ZTS and UTHR?
Citi Pharma's Short-Term Debt of ₨0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Citi Pharma's current Short-Term Debt is ₨0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current Short-Term Debt of ₨0.00 Mil. The current Short-Term Debt is ₨0.00 Mil. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current Short-Term Debt is ₨0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨73.40
Price